Navigation Links
AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles

- JMR-132 induces growth arrest or total regression when combined with docetaxel chemotherapy - JMR-132 could provide a new therapeutic approach to the treatment of early and metastatic breast cancer

"We are very pleased and encouraged with these results we have seen to date with JMR-132 which lend further credibility to our very promising oncology platform. By targeting patients suffering from breast cancer with confirmed GHRH receptor status, we believe we may increase our chances of success in future development programs with JMR-132 in this indication. This targeted approach is an additional example of personalized therapy which is becoming more and more the way of the future," said Dr. Jurgen Engel, Executive Vice President, Global R&D and COO of AEterna Zentaris.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global, pure play biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at www.aeternazentaris.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ ma
'"/>




Page: 1 2 3

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
10. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
11. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
Post Your Comments:
(Date:11/22/2014)...  Sprout Pharmaceuticals today announced positive preliminary results from a ... flibanserin up to 200 mg at bedtime had no next-day ... 20 th Annual Fall Scientific Meeting of the Sexual ... Miami . The Phase 1 ... Letter and the Formal Dispute Resolution that was filed in ...
(Date:11/22/2014)...  New data demonstrates that flibanserin, a novel, non-hormonal ... female sexual dysfunction, Hypoactive Sexual Desire Disorder (HSDD), does ... premenopausal women when taken at bedtime. The data was ... North America,s (SMSNA) 20th Annual Fall Scientific ... SMSNA accepted this study as a late breaking ...
(Date:11/22/2014)... MONMOUTH JUNCTION, N.J. , Nov. 21, 2014 ... immunotherapy company commercializing its European Union approved CytoSorb® ... countries worldwide, was awarded the Beacon of Light ... Annual Awards Celebration.  Dr. ... stated, "It is an honor to be recognized ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... Utah, Oct. 29 Researchers at Thomas Jefferson University in ... published an article in the Journal of Nuclear Medicine reporting ... detect malignant breast tumors [1] . "All ... the targeted VPAC1 receptors located on the plasma membrane of ...
... Qforma, an advanced analytics and predictive modeling company, ... of director of field operations. , "Erin is a ... the latest highlight in a year marked by company growth ... "Her combined background and expertise in analytics and healthcare will ...
Cached Medicine Technology:New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors 2New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors 3Qforma Appoints Erin McLaughlin as Director, Field Operations 2
(Date:11/22/2014)... 2014 Every year AlignLife clinics nationwide ... experience rapid growth in the Greenville, SC area in ... AlignLife of Simpsonville will be partnering with ... first annual Toy Drive. These six offices came together ... with this year's toy drive. With so many amazing ...
(Date:11/22/2014)... 2014 A new AlignLife Chiropractic & ... the downtown Greenville area. Dr. Chelsea Sineath, owner and ... to open her own clinic after working in another ... patients. , AlignLife believes that the body can ... focus on chiropractic care and rehabilitation to allow the ...
(Date:11/22/2014)... Cancer researchers in New York and Minnesota ... tunnels and the growth and spread of mesothelioma. ... the Surviving Mesothelioma website. , Doctors at Memorial ... have just released their study on tunneling nanotubes (TnTs), ... They found that mesothelioma cells contain many ...
(Date:11/22/2014)... 23, 2014 PrettyTailor , an ... a new big promotion. Customers can buy new dresses ... customers can visit its website. , As a matter ... occasion dresses. It mainly provides four types of wedding ... and flower girl dresses. It also provides a variety ...
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, has released its ... order to prepare for the wedding season. All of them ... , UWDress.com is a reliable company that has many years ... items -- formal wedding guest attire. This new collection comes ... and princess. As one of the leading companies in the ...
Breaking Medicine News(10 mins):Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2
... giving researchers the green light when they are on the ... prevent cancer. , The glow, the result of some tinkering ... know when powerful cancer-prevention signals similar to those spurred by ... turned on in the organism. , The chemical signaling system ...
... Lifesciences,Corporation (NYSE: EW ), a world leader ... announced today that it has,completed the sale of ... to C.R. Bard, consistent with the terms previously ... a leader in advanced cardiovascular disease,treatments, is the ...
... Optical coherence tomography,(OCT) is a unique imaging ... technology to date in the field of disease ... first commercialized for medical,imaging applications by Carl Zeiss ... diagnostic images for a variety of clinical applications.,In ...
... As the variety of tainted products widens, the concerns about ... 14 (HealthDay News) -- More than ever before, Americans are ... their mouths -- and with good reason. , In little ... of tainted products have formed their own peculiar food pyramid: ...
... technology will enhance the speed, ... service, ANNAPOLIS, Md., Jan. 14 CBaySystems ... BPO services, and M*Modal,providers of the industry,s most ... formed a strategic partnership., (Logo: http://www.newscom.com/cgi-bin/prnh/20070625/NEM130LOGO ...
... was beating in just 8 days , , SUNDAY, Jan. ... create transplantable hearts using stem cells from the recipients ... The technique, called whole organ decellularization, has been used ... in the Jan. 13 issue of Nature Medicine ...
Cached Medicine News:Health News:Fruit flies all aglow light the way to cancer prevention 2Health News:Fruit flies all aglow light the way to cancer prevention 3Health News:Optical Coherence Tomography Market to Top $800 Million by 2012 2Health News:Optical Coherence Tomography Market to Top $800 Million by 2012 3Health News:U.S. Food Safety: Home-Grown Problems Abound 2Health News:U.S. Food Safety: Home-Grown Problems Abound 3Health News:U.S. Food Safety: Home-Grown Problems Abound 4Health News:U.S. Food Safety: Home-Grown Problems Abound 5Health News:U.S. Food Safety: Home-Grown Problems Abound 6Health News:CBaySystems and M*Modal Enter Strategic Partnership 2Health News:CBaySystems and M*Modal Enter Strategic Partnership 3Health News:Biotechnology Builds a New Heart 2Health News:Biotechnology Builds a New Heart 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: